Equities research analysts expect GlycoMimetics Inc (NASDAQ:GLYC) to post ($0.26) earnings per share for the current quarter, according to Zacks Investment Research. Zero analysts have made estimates for GlycoMimetics’ earnings. The highest EPS estimate is ($0.25) and the lowest is ($0.27). GlycoMimetics reported earnings of ($0.36) per share in the same quarter last year, which would suggest a positive year over year growth rate of 27.8%. The business is expected to announce its next quarterly earnings report on Wednesday, March 7th.
On average, analysts expect that GlycoMimetics will report full-year earnings of ($1.12) per share for the current financial year, with EPS estimates ranging from ($1.15) to ($1.11). For the next financial year, analysts expect that the business will report earnings of ($0.86) per share, with EPS estimates ranging from ($1.73) to $0.34. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of analysts that cover GlycoMimetics.
GlycoMimetics (NASDAQ:GLYC) last announced its quarterly earnings results on Wednesday, November 8th. The biotechnology company reported ($0.24) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.28) by $0.04.
GlycoMimetics (NASDAQ GLYC) opened at $22.33 on Friday. The company has a market capitalization of $779.33, a P/E ratio of -18.01 and a beta of 3.40. GlycoMimetics has a 12 month low of $3.82 and a 12 month high of $25.20.
In other news, SVP Helen M. Thackray sold 2,000 shares of GlycoMimetics stock in a transaction that occurred on Friday, December 8th. The stock was sold at an average price of $15.01, for a total value of $30,020.00. Following the sale, the senior vice president now directly owns 148,615 shares in the company, valued at approximately $2,230,711.15. The sale was disclosed in a filing with the SEC, which is available through this link. 43.80% of the stock is currently owned by company insiders.
Several hedge funds have recently modified their holdings of the company. SG Americas Securities LLC bought a new stake in shares of GlycoMimetics in the 4th quarter worth approximately $103,000. Alyeska Investment Group L.P. grew its position in shares of GlycoMimetics by 2.6% in the 3rd quarter. Alyeska Investment Group L.P. now owns 358,962 shares of the biotechnology company’s stock worth $5,022,000 after buying an additional 8,962 shares during the last quarter. Citadel Advisors LLC grew its position in shares of GlycoMimetics by 161.9% in the 3rd quarter. Citadel Advisors LLC now owns 58,422 shares of the biotechnology company’s stock worth $817,000 after buying an additional 36,111 shares during the last quarter. EAM Investors LLC grew its position in shares of GlycoMimetics by 9.5% in the 3rd quarter. EAM Investors LLC now owns 371,030 shares of the biotechnology company’s stock worth $5,191,000 after buying an additional 32,285 shares during the last quarter. Finally, Dynamic Technology Lab Private Ltd grew its position in shares of GlycoMimetics by 43.7% in the 3rd quarter. Dynamic Technology Lab Private Ltd now owns 18,974 shares of the biotechnology company’s stock worth $265,000 after buying an additional 5,767 shares during the last quarter. Hedge funds and other institutional investors own 86.60% of the company’s stock.
GlycoMimetics Company Profile
GlycoMimetics, Inc is a clinical-stage biotechnology company. The Company focuses on the discovery and development of glycomimetic drugs. The Company operates through the identification and development of glycomimetic compounds segment. The Company is developing its lead drug candidate, GMI-1070 (Rivipansel), for the treatment of vaso-occlusive crisis (VOC), a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for GlycoMimetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlycoMimetics and related companies with MarketBeat.com's FREE daily email newsletter.